AB2 Bio gets $30m as Nippon Shinyaku takes U.S. Tadekinig rights

AB2 Bio has received a $30 million option exercise payment from Japan's Nippon Shinyaku, which has now formalised its exclusive right to commercialise Tadekinig alfa in the United States. The licence covers the treatment of Primary Monogenic IL-18-Driven Hyperinflammatory Syndrome in patients with NLRC4 and XIAP mutations, an ultra-rare and potentially fatal paediatric disease for which no FDA-approved therapy currently exists.

The deal builds on a 2025 option and licence agreement between the two companies and follows what AB2 Bio described as positive interactions with the FDA. Under the revised terms, AB2 Bio retains all rights to Tadekinig alfa outside the United States and retains U.S. rights for all indications beyond the lead genetic hyperinflammatory syndrome. The Lausanne-based biotech will continue to lead Biologics Licence Application preparation and U.S. regulatory activities. Closing remains subject to potential Hart-Scott-Rodino antitrust clearance.

Financial terms and regulatory backdrop

Beyond the $30 million upfront, AB2 Bio is eligible for up to $100 million in development milestones and up to $500 million in commercial milestone and royalty payments, bringing total potential receipts to $630 million when combined with the $6 million option fee paid last year. The structure reflects a relatively common model in rare-disease licensing: the originator retains the regulatory lead and ex-U.S. rights while the commercial partner absorbs U.S. launch risk in exchange for exclusivity.

Tadekinig alfa holds FDA Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Paediatric Disease Designation. The last of these is commercially significant: a successful BLA could generate a Priority Review Voucher, which have traded in recent years for sums that can offset a substantial portion of a rare-disease development programme's cost.

"Nippon Shinyaku's decision reflects the strength of our clinical programme and our shared confidence in Tadekinig alfa," said Dr Djordje Filipovic, Chief Executive Officer of AB2 Bio. "Together, we are well positioned to accelerate the delivery of this potential therapy to patients in the United States."

Market context

The ultra-rare paediatric hyperinflammatory space has attracted growing attention as genetic characterisation of autoinflammatory conditions has improved. NLRC4- and XIAP-associated disease are individually very small populations, but they represent a target that is genetically defined and mechanistically coherent, which makes regulatory pathways more tractable and supports orphan pricing assumptions. AB2 Bio's approach, a recombinant human IL-18 binding protein designed to neutralise excess free IL-18, targets the upstream driver of hyperinflammation rather than downstream cytokine cascades, which differentiates it from approaches such as IL-1 or IL-6 inhibition commonly used off-label in these patients.

Nippon Shinyaku has an established rare-disease franchise, particularly in neuromuscular conditions, and its decision to exercise the option signals confidence in the regulatory package AB2 Bio has assembled. Investors will focus on BLA submission timing and the FDA's response, given that Breakthrough Therapy Designation typically facilitates more frequent agency interaction but does not guarantee approval. The Priority Review Voucher eligibility adds optionality that could be meaningful to AB2 Bio's balance sheet regardless of the commercial trajectory of the asset itself.